Companies aim to combine blood-based circRNA biomarkers of disease biology and pathology with objective digital measures of cognition and function, to accelerate Alzheimer’s drug development today and create a scalable frontline care tomorrow.

SAN DIEGO and WASHINGTON, DC — Sepetmber 22, 2026 — Circular Genomics and Altoida today announced a collaboration combining Circular Genomics’ blood-based circular RNA (circRNA) biomarker platform with Altoida’s AI-powered Digital NeuroMarker™ platform.  The alliance is designed to advance an integrated biology-and-function approach to Alzheimer’s drug development and frontline healthcare by creating a first-of-kind, multimodal approach to improve early identification, patient stratification and longitudinal monitoring in Alzheimer’s disease (AD).

The collaboration brings together two complementary technologies that measure distinct aspects of disease etiology: blood-based molecular signatures of neurodegeneration and disease progression and objective digital measures of cognitive function. Together, the companies intend to demonstrate a new frontline diagnostic paradigm that combines objective measures of digital cognitive function and disease biology. 

The integrated approach is designed to create a scalable and efficient digital-first pathway that assesses cognitive function followed by a confirmatory disease biology and pathology blood test .  This pathway fits naturally into routine clinical workflows, reduces reliance on specialist-based assessment, and enables earlier interventions when they can have the greatest impact. As part of the collaboration, the companies plan to conduct real-world evidence studies evaluating the combined workflow in clinical research and frontline care settings, with the first pilots expected to launch later this year.

As the Alzheimer's therapeutic landscape shifts toward earlier intervention, the ability to identify individuals at risk before irreversible neurodegeneration has occurred is becoming one of the defining challenges in healthcare. The arrival of disease targeting therapies is reshaping Alzheimer’s care.  Yet most patients are still diagnosed too late because current diagnostic pathways remain fragmented, specialist-dependent, and difficult to scale. 

By combining molecular evidence of neurodegeneration with rapid and sensitive measures of functional change, the collaboration aims to generate evidence for a practical frontline workflow in which a 10-minute, self-administered objective cognitive function assessment can be completed before a circRNA blood biomarker testing is ordered to confirm disease biology.  This approach is designed to help reduce reliance on subjective specialist-based neuropsychological batteries that can take hours, streamline referral and treatment decisions, expand specialist capacity, monitor treatment effectiveness more objectively, and extend access beyond specialty neurology and memory clinics and into primary care].

The announcement follows the publication of Circular Genomics’ Nature Medicine study demonstrating that a blood-based circRNA signature predicts progression to symptomatic Alzheimer’s disease years before clinical onset and provides information complementary to established amyloid and tau biomarkers. It also builds on Altoida’s growing body of peer-reviewed research, including its recently published study in Alzheimer’s and Dementia: Diagnosis, Assessment & Disease Monitoring (DADM) demonstrating that the Digital NeuroMarker Platform can accurately detect mild cognitive impairment though a brief self-administered digital assessment, and, when deployed before blood biomarker testing, complements molecular diagnostics while improving the overall performance of a scalable frontline Alzheimer’s diagnostic workflow. Altoida is now preparing to initiate a pivotal study intended to support FDA clearance of the Digital NeuroMarker Platform for use across healthcare settings.

"The future of Alzheimer’s detection and precision neurology will not be built around a single biomarker; but on combining complementary biological signals with cognitive function assessment. Our CircPath^TM platform provides a fundamentally new window into the biology of neurodegeneration, and together with Altoida’s digital phenotyping capabilities we believe we can help accelerate therapeutic development while moving the field toward more personalized care earlier in the disease process." Said Paul Sargeant, CEO Circular Genomics.

"Biology and function answer different but essential questions:  which biological disease pathways are occurring and how are they affecting the individual patient in everyday life”, said Marc Jones, CEO Altoida,  “By studying them together, we aim to help drug developers enrich trials, stratify patients and measure change more precisely today, while generating the evidence required for a scalable frontline health care tomorrow.”

Together, Circular Genomics and Altoida aim to establish a new multimodal model for precision neurology: improving Alzheimer’s drug development today while enabling a future with a more scalable and efficient patient care path.

About Circular Genomics
Circular Genomics is the precision neurology leader pioneering circular RNA (circRNA) technology to develop next-generation molecular blood biomarker diagnostics. Leveraging the unique stability, brain enrichment, and biological relevance of circRNAs, the company is advancing a differentiated platform of blood-based tests designed to provide comprehensive, pathway-level insight into disease biology—with an initial focus on neurodegenerative disorders including Alzheimer's disease. Circular Genomics' proprietary circRNA platform (CircPathTM) is positioned to address critical unmet needs in early disease detection, patient stratification, and therapeutic development support, creating strategic value for healthcare systems, pharmaceutical partners, and patients.

About Altoida
Altoida is defining a new category in neurological care with a first-of-its-kind, AI- and AR-powered digital biomarker platform for clinical-grade cognitive and functional assessment. The company’s 10-minute, self-administered Digital NeuroMarker Platform captures millions of raw multimodal data points across motor, speech, and cognitive domains, designed to enable earlier and more objective detection of Mild Cognitive Impairment (MCI) and Alzheimer’s disease. Built on 20+ years of scientific research and tens of thousands of  tests across more than 20,000 participants in academic, research, and global pharma trials, Altoida’s Digital NeuroMarker Platform has been independently researched and peer-reviewed in Nature Digital Medicine. With an estimated 200M undiagnosed MCI patients worldwide, many of whom are eligible for new Alzheimer’s drugs, patients, payors and providers are demanding scalable solutions. With billing codes available, treatments on the market and more emerging, Altoida is uniquely positioned to meet this $7B+ near-term market and to empower clinicians to deliver earlier interventions when they matter most.  Altoida’s NeuroMarker platform is currently intended for investigational use only and has not received FDA clearance or approval and is not available for commercial sale.

Media Contact

Circular Genomics: Nhu Nguyen: nhu@circulargenomics.com

Altoida, Inc:  Jenna Hanson:  jenna.hanson@altoida.com

Pilot study to evaluate integration of AI/AR-based digital cognitive assessment to personalize care through understanding of individual neurophysiology

Washington, D.C. and Boston, MA — January 13, 2026 — Altoida, Inc., a pioneer in AI- and AR-powered digital diagnostics for neurological diseases, today announced a research collaboration with Mindspan, the cognitive care company focused on changing the trajectory of decline for patients with Alzheimer's disease and related conditions. Together, the companies will conduct an investigational pilot study evaluating the clinical, operational, and potential economic impacts of integrating Altoida’s rapid, AI/AR-powered digital NeuroMarker platform into Mindspan’s innovative cognitive care delivery model.

Designed for patient self-administration with minimal staff involvement, Altoida’s NeuroMarker platform is intended to support objective, scalable insight into cognitive and functional performance, addressing a key bottleneck in current diagnostic workflows.

Mindspan is an AI-native healthcare provider operating cognitive care specialty clinics and virtual care. The company delivers personalized, clinically proven interventions—including recently approved amyloid-reduction monoclonal antibody therapies—using an advanced digital twin approach to tailor care to each patient's unique neurobiology. Early, objective functional insight is central to Mindspan's care model, making Altoida's digital biomarkers a natural fit.

The study is designed to generate real-world evidence on whether adding Altoida’s rapid, AI/AR-powered digital cognitive assessment at the front end of care pathways can improve diagnostic efficiency, support earlier and more confident clinical decision-making, and enhance patient and clinician experience, while fitting seamlessly into routine clinical workflows. This approach reflects an emerging shift in neurology toward pairing emerging biological signals with scalable, objective measures of real-world function in front-line care. The pilot will enroll up to 100 adults presenting with cognitive concerns through Mindspan’s standard care pathways and will evaluate outcomes including time-to-decision, clinician efficiency, diagnostic performance, downstream utilization of specialty services and diagnostic resources, and patient experience.

“Healthcare systems are facing a growing volume of patients with cognitive concerns, yet frontline workflows still rely on outdated tools that were not designed for early, subtle, or rapidly scalable assessment,” said Marc Jones, CEO of Altoida. “This collaboration with Mindspan allows us to rigorously evaluate how a rapid digital-first NeuroMarker can strengthen real-world care pathways by delivering objective signals earlier, supporting clinicians, and ultimately helping patients move more efficiently toward clarity and appropriate next steps.”  

"Altoida's digital biomarkers capture detailed data across motor function, processing speed, and other cognitive domains—giving us a more precise picture of each patient's neurophysiology,” said Mirza Cifric, CEO of Mindspan. “By integrating this data into our AI models, we aim to identify which specific interventions will be most effective for each individual. This collaboration moves us closer to what patients need: care that is tailored to their unique cognitive needs, not a one-size-fits-all approach."

The pilot study is expected to initiate in Q1 2026, with results intended to inform future clinical, operational, and potential health-economic evaluations.  

To learn more about Altoida and its mission to redefine precision neurology, visit www.altoida.com. To learn more about Mindspan and its novel cognitive care pathways visit www.mindspan.co.

About Altoida

Altoida is defining a new category in neurological care with a first-of-its-kind, AI- and AR-powered digital biomarker platform for clinical-grade cognitive and functional assessment. The company’s 10-minute, self-administered Digital NeuroMarker Platform captures millions of raw multimodal data points across motor, speech, and cognitive domains, designed to enable earlier and more objective detection of Mild Cognitive Impairment (MCI) and Alzheimer’s disease.

Built on 20+ years of scientific research and over 42,000 tests across more than 20,000 participants in academic, research, and global pharma trials, Altoida’s Digital NeuroMarker Platform has been independently researched and peer-reviewed in Nature Digital Medicine. 

With an estimated 200M undiagnosed MCI patients worldwide, many of whom are eligible for new Alzheimer’s drugs, payors and providers are demanding scalable solutions. With billing codes available, treatments on the market and more emerging, Altoida is uniquely positioned to meet this $7B+ near-term market and to empower clinicians to deliver earlier interventions when they matter most.

For more information, visit www.altoida.com. Follow us on LinkedIn and X @altoida.

Altoida Media Contact:
Jenna Hanson
jenna.hanson@altoida.com

About Mindspan
Mindspan – The Cognitive Health Company – is on a mission to change the trajectory for individuals experiencing cognitive decline, including Alzheimer's disease and related dementias. An AI-native healthcare provider, Mindspan operates specialty clinics and virtual care, delivering actual patient care powered by an advanced digital twin that evaluates and personalizes interventions for each individual. The company brings patients access to clinically proven treatments not available through traditional healthcare, and is a leader in the rapidly evolving field of cognitive care.

For more information, please visit https://mindspan.co/

Mindspan Media Contact:
Rodrigo Martinez
rodrigo.martinez.dna@gmail.com

New appointments strengthen Altoida’s position as the inevitable standard for early detection and monitoring in a $7B+ and growing annual brain health diagnostics market

Washington, D.C. — BUSINESSWIRE — Altoida, Inc., a pioneer in AI- and AR-based digital diagnostics for neurological diseases, today announced the appointment of three new distinguished members to its already highly regarded Clinical and Scientific Advisory Board: Mona Flores, MD, former Global Head of Medical AI at NVIDIA; Bryan J. Hansen, PhD, former Director of Innovative Health, Portfolio Launch Strategy at Johnson & Johnson Innovative Medicine; and Michael Zuendel, founder of Legacy Bridge Private Family Offices, founder of “Initiative to change the ‘D-Word’”, and a nationally recognized Alzheimer's patient advocate. Their combined expertise across AI, pharma, and patient advocacy underscores Altoida’s leadership as the first category-defining digital brain health assessment platform, advancing through pivotal study and FDA submission, and preparing the market for rapid clinical adoption once cleared.

These appointments mark a pivotal moment for Altoida as it advances toward adoption of its Digital NeuroMarker Platform, a 10-minute, smart device-based, self-administered AR- and AI-powered tool that is designed to enable multimodal detection of subtle and early cognitive changes associated with neurodegenerative diseases like Alzheimer’s.

“The addition of Dr. Flores, Dr. Hansen, and Mr. Zuendel reflects Altoida’s unique position at the intersection of AI innovation, clinical validation, and patient advocacy,” said Marc Jones, CEO of Altoida. “Their expertise will be invaluable as we advance our pivotal study and expand pharma partnerships and, once FDA-cleared, support rapid clinical adoption of our Digital NeuroMarker Platform. Together, we are building the inevitable standard in digital brain health diagnostics and bringing precision neurology into frontline healthcare at scale.”

Dr. Mona Flores brings unmatched expertise in applying advanced AI to transform healthcare. At NVIDIA, she led global initiatives that harnessed cutting-edge computational power to revolutionize medical imaging, digital health, and drug discovery. She will help guide Altoida in advancing its AI-powered NeuroMarker Platform toward readiness and realization of broad clinical and commercial use.

“Altoida is the leader in applying AI to cognitive diagnostics, and I am honored to join at such a critical juncture,” said Dr. Flores. “Harnessing AI responsibly can redefine how we detect, diagnose, and treat neurological diseases like Alzheimer’s, and Altoida is setting the standard for how this should be done. I look forward to helping advance this vision for clinicians and patients worldwide.”

Dr. Bryan Hansen brings over a decade of experience in academia and pharma at the intersection of neuroscience, digital health, and clinical research. Most recently at Johnson & Johnson Innovative Medicine, he led the Portfolio Launch Strategy for Innovative Health, having previously directed the Data Science & Digital Health strategy across the neurodegeneration portfolio, where he advanced the use of digital health technologies to accelerate development and patient-centric trials.

“Altoida is uniquely positioned to bring AI-driven digital biomarkers into real-world use,” said Dr. Hansen. “By bridging rigorous science with practical deployment, Altoida’s Digital NeuroMarker Platform has the potential to revolutionize the development of new therapies and improve clinicians’ ability to detect and monitor disease at earlier stages.”

Complementing this scientific expertise, Altoida is honored to welcome Michael Zuendel to its Scientific Advisory Board. As an individual living with Alzheimer’s and the founder of the Initiative to change the “D-Word”, Zuendel brings the powerful voice of both advocate and patient. His perspective will help ensure Altoida’s innovations remain closely aligned with the real needs of patients, families, and the broader Alzheimer’s and cognitive health community.

“My mission has always been to help people understand that a diagnosis does not define them,” said Zuendel. “By joining Altoida, I hope to amplify the patient voice and ensure that the technologies shaping the future of brain health are built with empathy, dignity and hope, and with the recognition that earlier assessment, like Altoida’s, offers the hope for better planning, better care and better outcomes.”

To learn more about Altoida and its mission to redefine precision neurology, visit www.altoida.com.

About Altoida

Altoida is defining a new category in neurological care with a first-of-its-kind, AI- and AR-powered digital biomarker platform for clinical-grade cognitive and functional assessment. The company’s 10-minute, self-administered Digital NeuroMarker Platform captures millions of raw multimodal data points across motor, speech, and cognitive domains, designed to enable earlier and more objective detection of Mild Cognitive Impairment (MCI) and Alzheimer’s disease.

Built on 20+ years of scientific research and over 42,000 tests across more than 20,000 participants in academic, research, and global pharma trials, Altoida’s Digital NeuroMarker Platform has been independently researched and peer-reviewed in Nature Digital Medicine. 

With an estimated 200M undiagnosed MCI patients worldwide, many of whom are eligible for new Alzheimer’s drugs, payors and providers are demanding scalable solutions. With billing codes available, treatments on the market and more emerging, Altoida is uniquely positioned to meet this $7B+ near-term market and to empower clinicians to deliver earlier interventions when they matter most.

For more information, visit www.altoida.com. Follow us on LinkedIn and X @altoida.

Media Contact:
Jenna Hanson
jenna.hanson@altoida.com

TCB Capital Advisors proudly announces two of its partners, Altoida Inc. and Gregor Diagnostics Inc., have been recognized by the 2024 Merit Awards for Healthcare. These awards celebrate companies demonstrating groundbreaking advancements in medical technology, healthcare innovation, and patient care.

Altoida received the Gold Award for "Best Use of Artificial Intelligence," a testament to its leadership in digital health and AI applications that enhance the early detection of neurodegenerative diseases, including Alzheimer’s. Altoida’s pioneering NeuroMarker Platform utilizes a tablet-based application powered by augmented reality (AR) and artificial intelligence/machine learning (AI/ML) designed to deliver rapid and objective multi-modal assessment of cognitive health and function. The platform aim’s to equip frontline clinicians with clinical insights to enable earlier detection, personalized care and to lead to improved patient outcomes.

Gregor Diagnostics earned the Bronze Award in the “Innovations” category, underscoring the company's achievements in developing revolutionary diagnostic solutions. Gregor Diagnostics is dedicated to pioneering advancements in prostate cancer detection, aiming to deliver earlier and more precise diagnostics for better patient outcomes.

"It’s truly an honor to see Altoida and Gregor Diagnostics acknowledged for their groundbreaking work,” Sam Libby, President and Managing Director at TCB Capital Advisors, expressed. “The Merit Awards spotlight innovators who are reshaping the future of healthcare, and we at TCB are so proud to support such visionary leaders who are driving remarkable advancements in patient care and medical science.” 

The 2024 Merit Awards for Healthcare highlights outstanding achievements across various healthcare sectors, selecting winners based on their significant impact on improving healthcare delivery and innovation.

For more information please visit Altoida and Gregor Diagnostics. To learn more about TCB Capital Advisors, visit TCB Capital Advisors. 

About Altoida
Altoida is the leader in developing digital biomarkers for neurological conditions, including Alzheimer’s disease. Its innovative Altoida Digital NeuroMarker Platform leverages artificial intelligence and augmented reality (AR) to deliver objective and precise assessments of cognitive health. The platform uses a tablet-based app that offers a quick, self-administered series of motor, speech, and AR tasks, simulating daily activities to evaluate brain health. These tasks measure key cognitive metrics, including micro-movements, processing speed, reaction time, and spatial navigation. Altoida is a privately held, venture-backed diagnostics company with a proprietary platform built on over 20 years of scientific research. Its evidence-based technology has been featured in numerous global pharmaceutical studies and published in prestigious peer-reviewed journals, including Nature Digital Medicine.

About Gregor Diagnostics
Gregor Diagnostics Inc. is a molecular diagnostics company developing groundbreaking diagnostics for prostate cancer. Gregor Diagnostics’ patient-friendly test is sensitive enough to detect prostate cancer at the earliest stages of the disease and differentiate between indolent and aggressive cancer upon detection. Gregor Diagnostics is making early detection and less invasive identification and management of prostate cancer a reality while decreasing the overdiagnosis and overtreatment of indolent prostate cancer.

About TCB Capital Advisors

TCB Capital Advisors is a boutique investment bank and advisory firm focused on the healthcare and life sciences sectors. The firm specializes in advising clients with their buying, selling, investment, and growth strategies, leveraging decades of combined Wall Street and industry experience. TCB Capital Advisors offers a tailored approach, focusing on transaction advisory, corporate development, revenue growth, and post-transaction integration, working with clients across venture, growth, and middle-market verticals. Founded in 2023 by former members of the healthcare team at Piper Sandler, TCB Capital Advisors is headquartered in Houston, TX with offices/team members based in New York, North Carolina, and Tennessee. Securities are offered through Finalis Securities, LLC (member FINRA/SIPC). TCB Capital Advisors is not a registered broker-dealer, and Finalis Securities, LLC and TCB Capital Advisors are separated, unaffiliated entities. For more information, please visit www.tcbcapitaladvisors.com.

Media Contact:
Melinda Jackson Public Relations
melinda@melindajacksonpr.com

Leading pioneers in neuroscience, cognitive health, and digital biomarkers join Altoida’s mission to transform early Alzheimer's detection and care

Altoida, a leader in digital neuromarker diagnostics for neurological conditions, announced today the launch of its Scientific Advisory Board (SAB). The newly appointed experts will play a pivotal role in advancing Altoida’s artificial intelligence (AI) and augmented reality (AR)-based Digital NeuroMarker Platform.  The SAB will guide the Company in driving innovations in the early detection and intervention of cognitive and functional impairments tied to neurodegenerative disorders like Alzheimer’s disease.

“We are thrilled to welcome these prominent leaders to our Scientific Advisory Board. Their expertise will be invaluable as we continue to pioneer innovative approaches to brain health diagnostics,” said Marc Jones, Chief Executive Officer of Altoida, “Our goal is to empower clinicians with the tools to detect cognitive decline earlier and more accurately than ever before, giving patients the best possible chance for treatment and improved quality of life.”

The newly appointed members include prominent experts in neuroscience, clinical neurology, cognitive health, and medical technology. Their combined knowledge and experience will strengthen Altoida’s research and development initiatives, accelerating the company’s vision of providing a user-friendly, scalable platform designed to enabled early diagnosis and improves outcomes for patients globally. 

Altoida’s SAB members include:

Dr. Sharon Cohen, MD, FRCPC, a behavioral neurologist and Medical Director of the Toronto Memory Program, which she founded in 1996 to improve diagnosis, care, and treatment for individuals with or at risk of Alzheimer’s disease. Under her leadership, the Toronto Memory Program has grown into one of Canada's most active memory clinics and research sites, with a multidisciplinary team of 60. With over 30 years of clinical research experience, Dr. Cohen has served as Principal Investigator for over 180 pharmacological trials, earning recognition as a top center for Alzheimer’s research. She advises international boards and committees, consults for government and advocacy groups, and is known for her advocacy for patients with neurodegenerative diseases. Dr. Cohen is a frequent lecturer and media contributor on topics including medical ethics.

Dr. Michael Edgeworth, MD, FAAN, a board-certified neurologist and Chief Medical Officer at Nira Medical, focused on making neurological treatments accessible by empowering neurologists to deliver world-class care. Previously, he was Chief Population Health Officer at Octave, pioneering precision care for multiple sclerosis patients. From 2014 to 2021, he served as National Medical Director and Regional Medical Executive at Cigna, driving clinical innovation and value-based care. Dr. Edgeworth spent a decade in clinical neurology, including roles as Assistant Professor at Vanderbilt University and Chairman of the Department of Medicine at a community hospital. He completed his neurology residency and fellowship at Vanderbilt, holds a medical degree from the University of Mississippi, a master’s degree in clinical investigation from Vanderbilt University, and a B.S. in Chemistry from Mississippi State University.

John Harrison, Ph.D, a recognized cognition expert dedicated to helping people understand, maintain, and enhance their cognitive abilities. He is the Chief Scientific Officer at Scottish Brain Sciences, specializing in clinical trials and neuroscience research. Over the past 25 years, Prof. Harrison has supported over 80 CNS drug development organizations in integrating cognitive testing into their programs. His Alzheimer's research began with the AN1792 compound studies, where he developed the Neuropsychological Test Battery (NTB)—a tool now widely used in CNS treatment trials. He has also contributed significantly to psychiatric drug development, including the registration of Brintellix. Prof. Harrison is an Associate Professor at the AUmc Alzheimer Center, a Visiting Professor at King’s College London, and a Chartered Psychologist with over 100 publications.

Raymond G. Hill, B.Pharm., Ph.D, DSc (H.C.), FMedSci, Honorary Professor of Pharmacology at Imperial College London, where he researches the potential of substance P antagonists for treating opioid use disorder and teaches postgraduate courses on drug discovery. He chairs the College Impact Accelerator Panel for Healthy Society. Dr. Hill began his career in academia, transitioning to drug discovery research at Merck/MSD, where he led neuroscience research, globally overseeing pain and headache targets and contributing to the development of various drugs. He has held visiting professorships at Bristol, Surrey, and Strathclyde universities. Dr. Hill is President Emeritus of the British Pharmacological Society and has held advisory roles with the UK Government, Nuffield Council on Bioethics, and Cambridge University. He currently serves as Chair or NED for several pharmaceutical companies and has published over 250 papers on neuropharmacology.

Vijaya B. Kolachalama, Ph.D., Associate Professor of Medicine and Computer Science at Boston University (BU) and a founding member of BU's Faculty of Computing and Data Sciences. His lab focuses on biomedical machine vision and AI-based frameworks for clinical applications. Before joining BU, he was a Principal Member of Technical Staff at Draper Laboratory and a Postdoctoral Fellow at MIT. He also served as an ORISE fellow at the United States Food and Drug Administration.  His research, published in top journals like Nature Medicine and Brain, is supported by grants from the NIH, AHA, and others. Dr. Kolachalama is a Senior Member of IEEE, a Fellow of the American Heart Association, and actively collaborates with industry to bring AI-driven solutions to healthcare.

Ioannis Tarnanas, Ph.D, co-founder of Altoida and leading expert in digital biomarkers and cognitive health. With a background in neuroscience and digital health, Dr. Tarnanas has over two decades of experience working at the intersection of technology and medicine. His research focuses on using immersive technologies like augmented reality (AR) to assess brain health, and he has published extensively in high-impact journals. Dr. Tarnanas has collaborated with numerous academic institutions and global pharmaceutical companies to advance cognitive diagnostics and has been recognized for his work in developing tools that aid in early intervention and improved patient outcomes. He is a frequent speaker at international conferences on brain health and digital innovation.

The Scientific Advisory Board underscores Altoida’s commitment to advancing brain health research and driving meaningful progress in the fight against Alzheimer’s and other cognitive diseases.

About Altoida

Altoida is the leader in the development digital biomarkers for neurological conditions, including Alzheimer’s disease. Its innovative Altoida Digital NeuroMarker Platform leverages artificial intelligence and augmented reality (AR) to deliver objective and precise assessments of cognitive health. The platform uses a tablet-based app that offers a quick, self-administered series of motor, speech, and AR tasks, simulating daily activities to evaluate brain health. These tasks measure key cognitive metrics, including micro-movements, processing speed, reaction time, and spatial navigation. Altoida is a privately held, venture-backed diagnostics company with a proprietary platform built on over 20 years of scientific research. Its evidence-based technology has been featured in numerous global pharmaceutical studies and published in prestigious peer-reviewed journals, including Nature Digital Medicine.

For more information, please visit https://altoida.com.

Media Contact

Kimberly Ha

KKH Advisors

917-291-5744

kimberly.ha@kkhadvisors.com

December 19, 2023 08:00 AM Eastern Daylight Time

WASHINGTON--(BUSINESS WIRE)--Altoida, announced today results from the RADAR-AD consortium study, published in Nature Digital Medicine, which evaluated its augmented reality (AR) and machine learning (ML)-based digital cognitive assessment for the early identification of individuals with Alzheimer’s Disease (AD).

The ‘Remote Assessment of Disease and Relapse – Alzheimer’s Disease’ (RADAR-AD) study was an independent validation study with 121 enrolled participants over 50 years of age, which assessed cognitive and functional decline in AD using several remote monitoring technologies (RMTs) including the Altoida AR digital cognitive and functional assessment(the “Altoida AR app”). In contrast to traditional pen-and-paper clinical assessments, RMTs are designed to detect early impairment by allowing frequent and objective monitoring of function during tasks associated with instrumental activities of daily living (IADL) without the intervention of a clinician.

The study administered the Altoida AR app in amyloid beta-negative healthy control participants (HC, N=57), amyloid beta-positive cognitively normal preclinical AD participants (preAD, N=27) and prodromal AD participants (proAD, N=37). The Altoida AR app is an investigational test that consists of both motor and AR tasks. The motor tasks involve several short exercises testing fine motor skills and reaction times to set personalized reference values against population statistics for motor skills, visual abilities, and reaction times. The AR tasks are intended to simulate a complex IADL-like activity of a“place-and-find” task in which participants have to hide-and-seek virtual objects following specific instructions. Altoida’s AR app output is generated by an ML model trained to differentiate between cognitively normal and impaired participants.Leveraging data from internal device sensors, the Altoida AR app identifies digital biomarkers that have been trained from cohort data. The Altoida AR app-based tasks were administered in the clinic alongside a standard neuropsychological assessment battery. Additionally, participants utilized the Altoida AR app independently at home on their personal devices on a weekly basis for up to 8 weeks.

The study results showed that the Altoida AR app could distinguish healthy controls from individuals with preclinical AD and prodromal AD, and preclinical AD from prodromal AD, both with in-clinic and with at-home tests. The study results highlighted a significant finding: the Altoida AR app achieved a level of performance in preclinical Alzheimer's disease (AD)that is currently unattainable with standard cognitive tests. In addition, no learning effects were found for the Altoida AP app in this study.

"There is huge potential of digital devices and sensor technologies to enable objective and continuous monitoring ofAlzheimer’s disease symptoms,” said RADAR-AD academic leader Prof. Dag Aarsland, Chair of Old Age Psychiatry, King’sCollege London. “Altoida's AR cognitive assessment seems to be one of the most promising emerging technologies in this field, and the RADAR-AD study results indicate that Altoida’s test can detect subtle cognitive and functional changes in individuals with AD even before they show manifest any deficits. With the emergence of new disease-modifyingAlzheimer’s drugs, early diagnosis is now more important than ever.”

“Our feature in Nature Digital Medicine is a pivotal milestone in our mission to innovate and create responsible, evidence-based digital assessments for early identification of neurological diseases, including AD,” said Marc Jones, CEO, Altoida.“The RADAR-AD data underscores Altoida’s key near-term goal: facilitating the rapid identification of suitable study participants for AD treatment developers, monitoring their cognitive and functional responses throughout the study, and collecting relevant data to support both our partner’s and Altoida’s regulatory filings. Altoida is dedicated to ongoing innovation and enhancement across all aspects of the Altoida AR app to achieve this important goal.”

AR-based assessments are designed to simulate IADL and are promising tools to measure cognition and function needed for IADL in early AD both in clinic and home settings. RMTs, such as smartphone apps and smartwatches, are changing the way functional and cognitive performance are measured in AD. Due to their sensitivity, objectivity, and the option of long-term high-frequency measurements, RMTs have the potential to detect a subtle cognitive decline that occurs in the earliest stages of AD.

About RADAR-AD

RADAR-AD (Remote Assessment of Disease And Relapse – Alzheimer’s Disease) is a European project funded by theInnovative Medicines Initiative (IMI). RADAR-AD is looking at two very important areas in AD, namely functioning and technology. The term “functioning” refers to the activities a person carries out in his/her daily life. RADAR AD, looked at the impact that having AD has on a person’s functioning and how the way in which a person functions may change. RADAR-AD was also exploring how existing widely-used technology (e.g. smartphones, smart wristbands/fitness trackers, home-based sensors) could be used to measure the changes in a person’s functioning.

About Altoida Digital Neuro Signature™ (DNS) – Mild Cognitive Impairment (MCI)

Altoida’s investigational algorithm Digital Neuro Signature (DNS) – Mild Cognitive Impairment (MCI) combines motor and AR tasks. The digital score is an ordinal score ranging from 0 to 100, with higher scores designed to indicate better performance and lower scores designed to indicate a higher probability of having cognitive impairment. The score is based on a machine learning model trained to distinguish cognitively normal from cognitively impaired participants, using the data from the touch screen, accelerometer, and gyroscope, and based on ground truth data from clinically validated cohorts.

About Altoida

Altoida is a pioneer in developing digital biomarkers of neurological conditions using augmented reality and machine learning. Our technology platform is designed to enable an objective evaluation of an individual’s cognitive health, which may potentially allow for faster patient selection for clinical trials, as well as sensitive monitoring of disease progression and treatment response. Altoida’s mission is to enable a new era of precision neurology using digital biomarkers. Our proprietary evidence-based platform is founded on more than 20 years of scientific research and published in multiple peer-reviewed papers including Nature Digital Medicine. For more information, visit www.altoida.com. Follow us on Twitter @altoida.

Contacts

Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

October 24, 2023 09:00 AM Eastern Daylight Time

WASHINGTON--(BUSINESS WIRE)--Altoida, a pioneer in developing digital biomarkers of neurological disease using augmented reality (AR) and machine learning (ML), today announced results from a 188-participant study demonstrating its novel digital cognitive and functional assessment identified participants with mild cognitive impairment.

“We were proud to work with Altoida on the development of the new ADRD evidence library and are excited to introduce this new tool to the world to help define important measurement parameters for patients, their care partners, and physicians”Tweet this

The Altoida digital cognitive assessment is a research device based on AR and ML that simulates conducting activities of daily living, providing an objective measure of cognitive and functional abilities in approximately 10 minutes, compared to pen-and-paper neuropsychological tests that take approximately 60-90 minutes.

Altoida’s digital cognitive assessment also reported correlation with standard neuropsychological tests such as the Mini-Mental State Examination (MMSE), Free and Cued Selective Reminding Test (FCSRT) and the Trail Making Test (TMT).

“Digital biomarkers are increasingly utilized as exploratory endpoints and screening tools for inclusion in clinical trials. Digital cognitive assessments offer the potential to facilitate frequent and unbiased measurements of cognitive functional status, without the need of a trained rater,” said Marc Jones, CEO, Altoida. “We’re excited to report new study data showing Altoida’s digital cognitive assessment correlating with MMSE and other neuropsychological tests, and we look forward to expanding our research to other scales.”

Conducted as a dual-center, cross-sectional cohort study, 188 participants were enrolled from the Hospital Clinic Barcelona and the Barcelona-Beta Brain Research Center. Participants received a neurological evaluation, a neuropsychological test battery, and Altoida’s digital cognitive assessment. Participants were classified according to their clinical status as cognitively normal or as having mild cognitive impairment. The study evaluated the correlation between Altoida’s digital cognitive assessment and standard neuropsychological tests, including: the Mini-Mental State Examination (MMSE) - the Free and Cued Selective Reminding Test (FCSRT) - the Trail Making Test (TMT).

Altoida's digital cognitive assessment provides a Digital Neuro-Signature^™ (DNS-MCI) score correlated with classical neuropsychological tests that are commonly used as a battery when evaluating patients in clinical research and clinical practice. Using DNS-MCI<50 and MMSE<27 as patient classifier led to results that are mostly overlapping in high scores, with lower agreement on lower scores.

In addition, Altoida has been a key member of the Digital Health Measurement Collaborative Community (DATAcc) by DiMe’s Alzheimer’s Disease & Related Dementias (ADRD) project team, which recently released a new resource to guide the work of clinicians and researchers and leveraged digital tools for ADRD patients. DATAcc by DiMe's Library of Digital Measurement Products for ADRDis an invaluable resource for researchers and clinicians in the field who are assessing the available options for measurement in this population.

"We were proud to work with Altoida on the development of the new ADRD evidence library and are excited to introduce this new tool to the world to help define important measurement parameters for patients, their care partners, and physicians," said Piper Fromy, ADRD project head, Digital Medicine Society (DiMe). "DiMe's pre-competitive collaborations provide unique insights into ways to improve existing digital measures, develop new ones, and ultimately drive improvements and efficiencies in the emerging world of digital ADRD research."

About Altoida

Altoida is a pioneer in developing digital biomarkers of neurological conditions using augmented reality and machine learning. Our technology platform is designed to enable an objective evaluation of an individual’s cognitive health, which may potentially allow for faster patient selection for clinical trials, as well as sensitive monitoring of disease progression and treatment response. Altoida’s mission is to enable a new era of precision neurology using digital biomarkers. Our proprietary evidence-based platform is founded on more than 20 years of scientific research and published in multiple peer-reviewed papers including Nature Digital Medicine. For more information, visit www.altoida.com. Follow us on Twitter @altoida.

Contacts

Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

October 19, 2023 08:00 AM Eastern Daylight Time

WASHINGTON--(BUSINESS WIRE)--Altoida, a pioneer in developing digital biomarkers of neurological disease using augmented reality and machine learning, announced today it will be presenting poster presentations at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference, held in Boston and online, October 24-27, 2023.

“We look forward to presenting new data at CTAD 2023, that highlight Altoida’s latest research. Our presented data exemplifies our commitment to advancing the field of Alzheimer’s disease through cutting-edge technology and data-driven insights”Tweet this

"We look forward to presenting new data at CTAD 2023, that highlight Altoida’s latest research. Our presented data exemplifies our commitment to advancing the field of Alzheimer’s disease through cutting-edge technology and data-driven insights," said Marc Jones, CEO of Altoida. "Digital biomarkers have the potential to revolutionize our understanding of Alzheimer's and transform research, clinical trials, and patient diagnosis and treatment. We eagerly anticipate collaborative efforts with our partners in early disease detection and treatment."

Details of the poster presentations are below:

Poster Title: Correlation between Altoida’s digital cognitive assessment and standard neuropsychological tests in individuals with mild cognitive impairment and cognitively healthy volunteers
Poster Number: P189
Date/Time: Friday, October 27, 8 am to 5 pm
Presenter: Emmanuel Streel, Ph.D., Sr. Medical Affairs Director, Altoida

Poster Title: Building an Evidence Library of Digital Measurement Technologies to Accelerate Endpoint Development in Alzheimer’s Disease and Related Dementias Clinical Trials
Poster Number: P190
Date/Time: Friday, October 27, 8 am to 5 pm
Presenter: Emmanuel Streel, Ph.D., Sr. Medical Affairs Director, Altoida

About Altoida

Altoida is a pioneer in developing digital biomarkers of neurological conditions using augmented reality and machine learning. Our technology platform is designed to enable an objective evaluation of an individual’s cognitive health, which may potentially allow for faster patient selection for clinical trials, as well as sensitive monitoring of disease progression and treatment response. Altoida’s mission is to enable a new era of precision neurology using digital biomarkers. Our proprietary evidence-based platform is founded on more than 20 years of scientific research and published in multiple peer-reviewed papers including Nature Digital Medicine. For more information, visit www.altoida.com. Follow us on Twitter @altoida.

Contacts

Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

Research collaboration will identify new opportunities in the fight against Alzheimer’s and further validate the predictive diagnostic capabilities of Altoida’s software medical device.

October 18, 2021 08:00 AM Eastern Daylight Time

WASHINGTON--(BUSINESS WIRE)--Altoida, Inc. an AI company pioneering next-generation neurological disease diagnostics, announced the initiation of a five-year multicenter observational study with participation from thousands of patients representing all phases along the Alzheimer’s disease continuum.

“With this deeper understanding of Alzheimer’s pathology, we can define and develop comprehensive analytical models to predict disease progression with unprecedented accuracy.”Tweet this

This landmark research study will be launched in collaboration with Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”), and the Bioinformatics and Human Electrophysiology Laboratory (BiHeLab), Department of Informatics at Ionian University.

Altoida’s software device will use artificial intelligence (AI) to analyze cognitive test results to help diagnose neurological diseases, like Alzheimer’s disease, in the earliest phases. Their proprietary digital test activities use augmented reality (AR) to simulate real-world activities of daily living and can be completed on a smartphone or tablet in under ten minutes.

Altoida will evaluate its software and proprietary digital biomarker data alongside a breadth of clinical data (imaging, genomics, and other biomarker data) to validate the company’s device in detecting early neurocognitive impairments, which are currently undetectable by other technologies.

Often-overlooked impairments in cognition and function may be the key to predicting that an individual will progress from an early preclinical or Mild Cognitive Impairment (MCI) stage to full onset of a neurodegenerative disease, such as Alzheimer’s Disease. Diagnosing the condition that early, before symptoms have even begun to appear, could help physicians begin to treat at-risk patients, potentially delaying the onset or lessening the severity of the neurodegenerative disease.

BiHELab, a leading research center specializing in the application of mathematical modeling and machine learning techniques to neurodegenerative diseases, will apply analytical methods to help better quantify and understand hallmark pathological signatures, such as protein misfolding meta-analysis, and unlock key insights across the breadth of study data.

“We are launching the world’s most comprehensive study ever conducted in Alzheimer’s, and related neurological diseases,” said Travis Bond, CEO of Altoida. “By using Altoida’s device alongside traditional neuropsychological tests, imaging procedures (PET and MRI), cerebrospinal (CSF) fluid collection procedures, phenotypic assessments, and genomic assessments, this collaboration has the potential to unlock more about the pathology and the progression of Alzheimer’s than has ever been understood before, and to enable a new gold standard with Precision Neurology.”

"Through this collaborative study with Altoida and Ionian University, we look forward to gaining new insights into the Alzheimer's Disease continuum from various aspects of rich data sets,” said Keisuke Naito, Chief Ecosystem Officer of Eisai. “The insights obtained will not only contribute to supporting dementia patients, but also to informing care for those concerned about developing dementia.”

“This study has the potential to quantify the contribution of many different parameters, patterns, and signatures in the progression from Mild Cognitive Impairment to Alzheimer’s,” said Professor Panagiotis Vlamos, Scientific Director at BiHELab. “With this deeper understanding of Alzheimer’s pathology, we can define and develop comprehensive analytical models to predict disease progression with unprecedented accuracy.”

In July 2021, Altoida won FDA Breakthrough Device Designation for development of their device to use artificial intelligence to predict the likelihood that an individual aged 55+ with Mild Cognitive Impairment will convert to Alzheimer’s disease. Altoida also secured funding from the Alzheimer’s Drug Discovery Foundation Diagnostics Accelerator, co-founded by Bill Gates, to evaluate their device for predictive diagnosis of Alzheimer’s in the preclinical phase.

About Altoida, Inc.

Altoida, Inc is creating a new gold standard in brain health with Precision Neurology. Our innovative approach combines novel digital biomarkers (dBM) with immersive augmented reality (AR) and powerful artificial intelligence (AI). The result is our validated device and platform built on more than twenty years of cutting-edge scientific research. Our products are backed by peer-reviewed publications and multinational clinical trials, and are built by our expert team of scientists, clinicians and engineers. Altoida, Inc. is funded by M-Ventures, Eisai Innovation, Hikma Ventures, GreySky Venture Partners, FYRFLY, Alpana Ventures and VI Partners. For more on Altoida, please visit www.altoida.com and connect with us on LinkedIn and Twitter.

Contacts

For Altoida, Inc.
Henry Peck
+1 (240) 720-7538
pr@altoida.com

WASHINGTON--(BUSINESS WIRE)-- Altoida, Inc, a pioneer in developing digital biomarkers of neurological disease using augmented reality and machine learning, announced today the appointment of industry veteran Marc Jones as Chief Executive Officer. Jones will also serve on the company’s Board.

"We are thrilled that Marc is joining Altoida as CEO, as the company transitions from clinical proof-of-concept to its commercial expansion phase,” said William (Bill) Moffitt, Chairman of the Board, Altoida. “Marc is a visionary executive with a proven track record of successfully guiding healthcare companies through important commercial milestones. He brings invaluable diagnostic industry experience, and an extensive history of operational success.”

Jones brings invaluable experience from both public and private diagnostic companies, and he has served in various leadership positions in the life science industry over the past 25 years. Most recently, Jones was the COO & CFO of binx health, a first-of-kind, commercial, digital healthcare technology and molecular diagnostics company. While at binx, he raised approximately $120M in equity and debt capital. Prior to binx health, he was COO & CFO at Good Start Genetics, where he played a pivotal role in the successful turnaround of the company to record business growth culminating in its sale to publicly-traded Invitae (NYSE:NVTA).

Prior to Good Start Genetics, Jones served as the CFO of T2 Biosystems, where he oversaw the company’s successful public offering, raising nearly $100 million in capital, and helped drive the early commercialization of the company’s first FDA cleared IVD product. Previously, Jones was CFO at Crashlytics (acquired by Twitter), Ivenix (acquired by Fresenius Kabi) and CHiL Semiconductor (acquired by International Rectifier). Earlier in his career, Jones held several corporate finance positions ranging from Fortune 50 companies to high-growth startups.

“I’m excited to lead Altoida to its next phase of extraordinary growth. A groundbreaking revolution is sweeping through the diagnostics industry, propelled by cutting-edge technologies driven by machine learning. These technologies have the potential to revolutionize drug development in neurological clinical trials along with treatment and care for individuals affected by neurological diseases,” said Marc Jones, CEO, Altoida. “With the emergence of digital biomarkers, we can unlock previously inaccessible data and gain real-time actionable insights. This presents an immense opportunity to harness these innovative technology solutions for new research and clinical applications, and I look forward to leading the Altoida team through its next stage of growth.”

“It is an exciting time for the Alzheimer and neurodegenerative disease space, with its recent therapeutic breakthroughs. However, there remains a huge unmet need for faster, more sensitive methods to detect cognitive as well as disease-modifying changes in these disorders and their clinical trials. Altoida is the leading company developing proprietary next-generation neurotechnology digital biomarkers using machine learning and augmented reality, and we’re excited to have Marc lead the company as CEO,” said Therese Maria Liechtenstein, Ph.D., Investment Director at M Ventures.

Jones is currently on the Board of Directors at Progentec Diagnostics and Pathfinder Health. He received his MS in Finance from Northeastern University and his BA in Finance at Southern New Hampshire University.

About Altoida, Inc.

Altoida is a pioneer in developing digital biomarkers of neurological conditions using augmented reality and machine learning. Our technology platform is designed to enable an objective evaluation of an individual’s cognitive health, which may potentially allow for faster patient selection for clinical trials, as well as sensitive monitoring of disease progression and treatment response. Altoida’s mission is to enable a new era of precision neurology using digital biomarkers. Our proprietary evidence-based platform is founded on more than 20 years of scientific research and published in multiple peer-reviewed papers including Nature Digital Medicine. For more information, visit www.altoida.com. Follow us on Twitter @altoida.

Media Contact

Kimberly Ha

KKH Advisors

917-291-5744

kimberly.ha@kkhadvisors.com